Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Dec 06, 2023
TickeronGET DAILY SIGNALS
Eyeing Success: Ophthalmology Tickers $HALO, $ALIM, $REGN, $GKOS, $ADVM, $KALA, $EYPT, $BHC Surge with +33.31% Weekly Performance Boost

Eyeing Success: Ophthalmology Tickers $HALO, $ALIM, $REGN, $GKOS, $ADVM, $KALA, $EYPT, $BHC Surge with +33.31% Weekly Performance Boost

Robots for this group tickers :
Day Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)
 - 30-day Annualized Return +171%
Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA) - 30-day Annualized Return +97%

The past week has seen a remarkable surge in ophthalmology companies, with a collective performance increase of +33.31%. This surge has caught the attention of investors and analysts alike, particularly focusing on eight key stocks in this sector: HALO, ALIM, REGN, GKOS, ADVM, KALA, EYPT, and BHC.

Positive Outlook and Predictions: The positive outlook for this group is substantiated by the Volume Indicator and the Stock Fear & Greed Index. According to Tickeron, a reliable forecasting platform, there is a predicted further increase of over 4.00% within the next month with a likelihood of 59%. Additionally, the daily ratio of advancing to declining volumes over the last month was 1 to 1.29.

Individual Stock Analysis:

1. ALIM - A Promising Uptrend:

  • On November 2, 2023, ALIM exhibited a strong bullish signal as the 10-day Moving Average crossed above the 50-day moving average.
  • Historical data shows that in 14 out of 15 past instances of such a crossover, the stock continued to move higher over the following month, indicating a 90% probability of a continued upward trend.
  • The current price is $3.54, having crossed the support line at $3.26 and trading between $4.36 resistance and $3.26 support lines.
  • The price experienced a +5% uptrend throughout the month, with a minor downtrend of -2% in the week of 11/27/23 - 12/04/23.

2. REGN - Momentum Shifting Upward:

  • REGN's RSI Oscillator moved out of oversold territory on November 1, 2023, signaling a potential shift from a downward to an upward trend.
  • Historical analysis based on 25 similar instances indicates an 80% probability of the stock moving higher.
  • The current price is $823.32, having crossed the resistance line at $820.32 and trading between $828.71 support and $820.32 resistance lines.
  • The stock experienced a +4% uptrend throughout the month, with a further +3% uptrend in the week of 11/27/23 - 12/04/23.

3. GKOS - Three-Day Uptrend:

  • GKOS has shown a notable +5.05% uptrend, rising for three consecutive days on December 1, 2023.
  • A three-day upward movement is considered a bullish sign, and historical data suggests a 77% probability of further upward movement.
  • The current price is $65.01, above the highest resistance line found by A.I. at $61.84.
  • The month of 11/27/23 - 12/04/23 saw an impressive +8% uptrend after a preceding -8% downtrend throughout the month.

Summary: The ophthalmology sector, as reflected by HALO, ALIM, REGN, GKOS, ADVM, KALA, EYPT, and BHC, is currently exhibiting a robust performance, backed by positive indicators and historical trends. Investors are advised to closely monitor these stocks, considering their recent positive movements and the high probability of continued upward trends. While market dynamics are subject to change, the present conditions suggest a favorable outlook for these ophthalmology companies.

Related Ticker: REGN, ALIM, HALO, GKOS, ADVM, KALA, EYPT, BHC

Contributor

Dem Sem's AvatarDem Sem|Expert

REGN in upward trend: 10-day moving average moved above 50-day moving average on October 26, 2026

The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 57 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.

The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 30 of 49 cases over the following month. The odds of a continued upward trend are 61%.

REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 203 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 186 of 264 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Bearish Trend Analysis

The 10-day RSI Indicator for REGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 23 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 64 cases where REGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.936) is normal, around the industry mean (3.498). P/E Ratio (21.599) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (130.981) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (440.869).

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 5%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -13%. LABT experienced the highest price growth at 113%, while KPTI experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 12% and the average quarterly volume growth was -27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -5 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of medicines for the treatment of serious medical conditions

Industry Biotechnology

Industry
Biotechnology
Address
777 Old Saw Mill River Road
Phone
+1 914 847-7000
Employees
15410
Web
https://www.regeneron.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
XRPN fell -9.70% in early regular-session trading on Tuesday, sliding from Monday's $10.41 close to $9.40. The decline follows a November 9 SEC prospectus disclosing a committed equity facility with Cantor to sell up to 5.2 million new Class A shares at 97% of the volume-weighted average price, implying up to roughly 16.7% potential dilution.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.